COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion
T cell scarcity in tumor tissues poses a critical challenge to cancer immunotherapy. Here we manipulate the tumor vasculature, an essential regulator of immune cell trafficking, to reinvigorate anti-tumor T cell responses in "cold" tumors. We show that ectopic pan-endothelial expression of COUP-TFII, a master transcription factor for venous development, induces molecular programs of post-capillary venules in tumor endothelium. Venular reprogramming selectively promotes T cell recruitment into tumors, inhibits tumor growth in mouse models of breast and pancreatic cancers, and sensitizes tumors to immune checkpoint blockade and adoptive T cell transfer therapies. Mechanistic studies show that enhanced recruitment of anti-tumor T cells and tumor inhibition are mediated by COUP-TFII-induced vascular adhesion receptors. Our study supports a pivotal role of vascular endothelial cells in governing tumor immune evasion, and proposes venular reprogramming as a therapeutic strategy to bolster anti-tumor immunity and immunotherapy.
Authors
- Junliang Pan (ORCID: https://orcid.org/0000-0002-2373-0917)
- Yu Zhu (ORCID: https://orcid.org/0000-0002-3250-6546)
- Eugene C. Butcher (ORCID: https://orcid.org/0000-0001-8786-7907)
- Kevin Brulois (ORCID: https://orcid.org/0000-0002-6024-6075)
- Thanh T Dinh
Institutions
- Palo Alto Veterans Institute for Research (US)
- Stanford Medicine (US)
- San Jose State University (US)
- Stanford University (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1038/s41467-025-62399-1
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Cancer Research Institute
- American Heart Association
- Tobacco-Related Disease Research Program
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Cancer Institute
- Stanford Cardiovascular Institute, School of Medicine, Stanford University